Clinical Cancer Research · 2023 · 19 citations · 47 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsT Cell Responses To TumorsTumor-infiltrating LymphocytesCd4 Positive T Cell ResponsesCd4 Positive T CellsCd4+ Tumor-infiltrating LymphocytesImmune Checkpoint Blockade ResistanceImmune Checkpoint ResistanceImmune Effector MoleculesMhc Class Ii MoleculesT Cell Cytotoxicity
PURPOSE: Impaired MHCI-presentation and insensitivity to immune effector molecules are common features of immune checkpoint blockade (ICB)-resistant tumors and can be, respectively, associated with loss of β2 microglobulin (B2M) or impaired IFNγ signaling. Patients with ICB-resistant tumors can respond to alternative immunotherapies, such as infusion of autologous tumor-infiltrating lymphocytes (TIL). CD4+ T cells can exert cytotoxic functions against tumor cells; however, it is unclear whether CD4+ T-cell responses can be exploited to improve the clinical outcomes of patients affected by ICB-resistant tumors. EXPERIMENTAL DESIGN: Here, we exploited CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 gene editing to reproduce immune-resistant tumor phenotypes via gene knockout (KO). To determine the role of cytotoxic CD4+ TILs in ICB-resistant tumors, we investigated CD4+ TIL-mediated cytotoxicity in matched pairs of TILs and autologous melanoma cell lines, used as a model of patient-specific immune-tumor interaction. Around 40% of melanomas constitutively express MHC Class II molecules; hence, melanomas with or without natural constitutive MHC Class II expression (MHCIIconst+ or MHCIIconst-) were used. RESULTS: CD4+ TIL-mediated cytotoxicity was not affected by B2M loss but was dependent on the expression of CIITA. MHCIIconst+ melanomas were killed by tumor-specific CD4+ TILs even in the absence of IFNγ-mediated MHCII upregulation, whereas IFNγ was necessary for CD4+ TIL-mediated cytotoxicity against MHCIIconst- melanomas. Notably, although tumor-specific CD4+ TILs did not kill JAK1KO MHCIIconst- melanomas even after IFNγ stimulation, sensitivity to CD4+ TIL-mediated cytotoxicity was maintained by JAK1KO MHCIIconst+ melanomas. CONCLUSIONS: In conclusion, our data indicate that exploiting tumor-specific cytotoxic CD4+ TILs could help overcome resistance to ICB mediated by IFNγ-signaling loss in MHCIIconst+ melanomas. See related commentary by Betof Warner and Luke, p. 3829.
47
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky, Ángel García-Díaz, Daniel Sanghoon Shin et al. · New England Journal of Medicine · 2016 · 3.2K citations · Full text
Medicine, Immunology, Oncology +17
Janis M. Taube, Robert A. Anders, Geoffrey D. Young et al. · Science Translational Medicine · 2012 · 2.1K citations
Life Sciences, Immunology, Oncology +14
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Ángel García-Díaz, Daniel Sanghoon Shin, Blanca Homet Moreno et al. · Cell Reports · 2017 · 1.9K citations · Full text
Life Sciences, Immunology, Oncology +17
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Eric Tran, Simon Turcotte, Alena Gros et al. · Science · 2014 · 1.7K citations · Full text
Life Sciences, Immunology, Oncology +17